Comparing the cost-effectiveness of SGLT2i versus mineralocorticoid antagonists

FHS
June 19, 2023
2:43 pm

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are approved for heart failure with reduced ejection fraction (HFrEF).

How your brain plans a route: A peek into navigational thinking

A study in Scientific Reports unveils the human brain’s hierarchical processing for navigation, beginning with low-level 2D image analysis, followed by simultaneous mid-level 3D and

March 8, 2024

UVXY ETF Analysis as The VIX Plums new lows, here are my thoughts on UVXY ETF and volatility

June 7, 2023

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575 million, lowering hopes of a buyout

Cytokinetics, a drugmaker that is expected to soon launch a promising new heart therapy called aficamten, said Wednesday that it had agreed to pay biotech

May 22, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.